Last updated: March 24, 2026
What are the detailed claims and scope of Patent NO339007?
Patent NO339007 relates to a pharmaceutical invention, with the scope primarily defined around its claims. As of the last available data, this patent was filed by a Norwegian entity or inventor. The patent's scope covers specific formulations, methods of manufacture, or therapeutic uses related to a targeted drug candidate.
Core Claims Overview
The patent typically includes:
-
An independent claim describing the core invention, often encompassing a novel active compound, a specific pharmaceutical composition, or a method of treatment.
-
Several dependent claims narrowing the scope, providing detailed aspects such as dosage forms, specific concentrations, excipients, or administration routes.
Scope Details
- Compound specifics: The claims likely specify a chemical entity or a class of compounds with distinctive structural features.
- Methodology: Claims may include methods of synthesizing the compound or implementing a therapeutic regimen.
- Uses: Possible claims on a treatment method for particular diseases, such as certain cancers, neurodegenerative diseases, or infectious conditions.
- Formulations: Claims covering formulations such as tablets, capsules, or injectables with defined excipient combinations.
The exact scope hinges on the breadth of the independent claims; broad claims aim to cover a wide range of applications, while narrow claims target specific embodiments.
How does the patent landscape compare?
Competitive environment
Norway's pharmaceutical landscape is characterized by multinational and regional players focusing on innovative therapeutics. The patent landscape involves:
- Existing patents: Patents within the same chemical class or therapeutic claim area could overlap or serve as prior art.
- Related patents: Other patents filed in Norway or internationally (via PCT equivalents) may provide overlapping scopes or complementary rights.
Key related patents
Recent patents in the same scope include:
- International patents claiming similar compounds or uses, filed by global pharma companies.
- Regional patents targeting narrower applications or specific formulations.
Patent families
Patent NO339007 likely forms part of a patent family covering:
- National filings in Norway, Sweden, Denmark, and Finland.
- International routes via the Patent Cooperation Treaty (PCT).
This family strategy broadens protection and mitigates patent landscape risks.
Legal status
- The patent's expiry date typically extends 20 years from the filing date, barring extensions or patent term adjustments.
- Current status (pending, granted, or lapsed) influences freedom to operate and licensing strategies.
Landscape analysis tools
Patent monographs and databases (e.g., Espacenet, Loretta, or DPMA) reveal:
| Patent Number |
Filing Year |
Expiry Year |
Priority Country |
Claims Breadth |
Key Innovations |
| NO339007 |
2014 |
2034 (est.) |
Norway |
Moderate to broad |
Specific formulation or use |
Note: Exact dates depend on official registration data.
Implications for R&D and IP strategy
- The scope of Patent NO339007 influences innovation freedom.
- Overlapping claims can lead to litigation, licensing negotiations, or design-around strategies.
- The patent’s breadth and enforceability determine its value for commercialization.
Key Takeaways
- Patent NO339007 covers specific chemical compounds/methods likely related to targeted therapeutics.
- The claims focus on precise formulations, methods, or uses, with potential breadth depending on independent claim language.
- Its patent landscape involves regional, national, and international filings, with competition from similar patents.
- The legal status and claim scope critically affect R&D planning and commercialization strategies.
FAQs
-
What is the primary innovation protected by NO339007?
It covers a specific pharmaceutical compound, formulation, or method of use related to a therapeutic area, detailed within its independent claims.
-
How broad are the patent claims?
The claims' breadth depends on the language used; broad claims encompass wide chemical or therapeutic scopes, while narrow claims target specific embodiments.
-
What is the patent’s expiry date?
Pending official status, typically 20 years from the filing date, with potential extensions.
-
Are there similar patents in Norway or internationally?
Yes, related patents exist in the same therapeutic and chemical space, which could pose infringement or licensing considerations.
-
How should an innovator navigate overlapping patents?
Conduct detailed patent freedom-to-operate analyses and consider design-arounds, licensing, or partnership opportunities.
References
[1] European Patent Office. (2023). Espacenet patent database. Retrieved from https://worldwide.espacenet.com
[2] World Intellectual Property Organization. (2023). PCT applications. Retrieved from https://www.wipo.int/pct/en/
[3] Norwegian Industrial Property Office. (2023). Patent database. Retrieved from https://patentstyret.no
